- Home
- IOVA vs NVGS Comparison
IOVA vs NVGS Comparison
Compare IOVA & NVGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- NVGS
- Stock Information
- Founded
- IOVA 2007
- NVGS 1997
- Country
- IOVA United States
- NVGS United Kingdom
- Employees
- IOVA N/A
- NVGS N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- NVGS Marine Transportation
- Sector
- IOVA Health Care
- NVGS Consumer Discretionary
- Exchange
- IOVA Nasdaq
- NVGS Nasdaq
- Market Cap
- IOVA 975.1M
- NVGS 1.1B
- IPO Year
- IOVA N/A
- NVGS N/A
- Fundamental
- Price
- IOVA $1.83
- NVGS $16.29
- Analyst Decision
- IOVA Buy
- NVGS Strong Buy
- Analyst Count
- IOVA 11
- NVGS 2
- Target Price
- IOVA $10.80
- NVGS $21.50
- AVG Volume (30 Days)
- IOVA 14.8M
- NVGS 315.5K
- Earning Date
- IOVA 11-06-2025
- NVGS 11-04-2025
- Dividend Yield
- IOVA N/A
- NVGS 1.22%
- EPS Growth
- IOVA N/A
- NVGS 12.51
- EPS
- IOVA N/A
- NVGS 1.26
- Revenue
- IOVA $241,525,000.00
- NVGS $566,889,000.00
- Revenue This Year
- IOVA $68.14
- NVGS $1.23
- Revenue Next Year
- IOVA $56.64
- NVGS $3.02
- P/E Ratio
- IOVA N/A
- NVGS $13.04
- Revenue Growth
- IOVA 636.99
- NVGS 1.19
- 52 Week Low
- IOVA $1.64
- NVGS $10.55
- 52 Week High
- IOVA $12.51
- NVGS $17.53
- Technical
- Relative Strength Index (RSI)
- IOVA 34.71
- NVGS 61.91
- Support Level
- IOVA $1.94
- NVGS $16.12
- Resistance Level
- IOVA $2.20
- NVGS $16.54
- Average True Range (ATR)
- IOVA 0.14
- NVGS 0.31
- MACD
- IOVA -0.04
- NVGS 0.16
- Stochastic Oscillator
- IOVA 3.31
- NVGS 88.33
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). Company play a vital role in theglobalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users and commodity traders.